MEDIZINISCHE UNIVERSITAET WIEN

Their core work

The Medical University of Vienna is Austria's largest medical research university, combining clinical medicine with translational research across oncology, immunology, metabolic disease, and advanced biomedical imaging. They develop diagnostic and therapeutic approaches — from optical coherence tomography for eye and brain diseases to personalized treatment strategies for cancer, diabetes, and autoimmune conditions. Their strength lies in bridging laboratory discoveries with clinical application through large multi-national trials, biomarker validation, and pharmacogenomics programs. They also serve as a major European training hub through Marie Skłodowska-Curie doctoral and fellowship programs in biomedicine.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), MedUni Wien focused heavily on fundamental disease biology — cancer mechanisms, regenerative medicine, diabetes cell therapies, and leukemia — alongside building research infrastructure and doctoral training networks. From 2019 onward, a clear shift emerged toward precision diagnostics and data-driven medicine: optical coherence tomography became their most frequent keyword, joined by bioinformatics, biomarkers, personalised medicine, disease registries, and clinical trial phases (I/II). This evolution reflects a move from understanding disease mechanisms to translating that knowledge into measurable, patient-facing diagnostic and treatment tools.

MedUni Wien is increasingly investing in imaging-based diagnostics (especially OCT), biomarker-driven personalised therapies, and bioinformatics infrastructure — positioning itself as a translational bridge between clinical data and individualized treatment.

How they like to work

MedUni Wien operates primarily as an active partner (84 of 120 projects), but has meaningful coordinator experience with 29 led projects — particularly in imaging, autoimmunity, and stem cell research. With 1,127 unique consortium partners across 49 countries, they function as a high-connectivity hub rather than a loyal-partner institution, making them easy to integrate into new consortia. Their mix of large Research and Innovation Actions (56 RIA projects) and training networks (19 MSCA-ITN) shows they are comfortable in both research-intensive and capacity-building roles.

One of the most broadly connected medical universities in H2020, with 1,127 unique consortium partners spanning 49 countries. Their network reaches well beyond the EU into global health research collaborations, with particularly dense connections across Western European clinical research hubs.

What sets them apart

MedUni Wien combines deep clinical access (as a university hospital) with world-class expertise in optical coherence tomography — a niche where few European medical universities can match their concentration of projects (OPTIMALZ, OCTCHIP, GSAORI). Their dual strength in imaging technology development and large-scale clinical validation makes them an ideal partner for projects that need to move from lab prototype to patient-tested diagnostic. Additionally, their pharmacogenomics and biomarker work (U-PGx, BEAt-DKD) positions them at the intersection of data science and clinical medicine, a combination increasingly demanded by Horizon Europe calls.

Highlights from their portfolio

• STEMMING-FROM-NERVE
  Largest single coordinator grant (EUR 1.96M) investigating neural crest-derived glia in organ regeneration — reflects their strength in fundamental developmental biology
• U-PGx
  EUR 1.43M contribution to a flagship pharmacogenomics programme making genetic data actionable in clinical prescribing across Europe
• OCTCHIP
  Coordinator of a project miniaturizing optical coherence tomography onto a chip — represents their signature convergence of optics engineering and clinical ophthalmology